Bausch says it expects US FDA to approve its ANDA for the first preservative-free OTC eye drop for ocular itching associated with allergic conjunctivitis in the second half of 2020. The firm reports its Lumify redness relief drops generated sales of $63m for 2019.

BeiGene and Novartis penned a potential $2.2bn collaboration for the development, manufacture, and commercialization of BeiGene’s humanized IgG4 anti-PD-1 monoclonal antibody tislelizumab in the US, Canada, Mexico, member countries of the EU, the UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. Steris entered into a definitive agreement to acquire Cantel Medical, a global provider of infection prevention products and services primarily to endoscopy and dental customers. The total enterprise value of the deal is estimated at $4.6bn. Financing reached $10.5bn in biopharma, $984m in device, and $2.7bn in diagnostics.

During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.